AU2003287833A1 - Use of aglycon protopanaxatriol in cancer therapy - Google Patents

Use of aglycon protopanaxatriol in cancer therapy

Info

Publication number
AU2003287833A1
AU2003287833A1 AU2003287833A AU2003287833A AU2003287833A1 AU 2003287833 A1 AU2003287833 A1 AU 2003287833A1 AU 2003287833 A AU2003287833 A AU 2003287833A AU 2003287833 A AU2003287833 A AU 2003287833A AU 2003287833 A1 AU2003287833 A1 AU 2003287833A1
Authority
AU
Australia
Prior art keywords
cancer therapy
protopanaxatriol
aglycon
aglycon protopanaxatriol
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287833A
Inventor
Dong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panagin Pharmaceuticals Inc
Original Assignee
Panagin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panagin Pharmaceuticals Inc filed Critical Panagin Pharmaceuticals Inc
Publication of AU2003287833A1 publication Critical patent/AU2003287833A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003287833A 2002-12-19 2003-12-19 Use of aglycon protopanaxatriol in cancer therapy Abandoned AU2003287833A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43444102P 2002-12-19 2002-12-19
US60/434,441 2002-12-19
PCT/CA2003/001954 WO2004056371A1 (en) 2002-12-19 2003-12-19 Use of aglycon protopanaxatriol in cancer therapy

Publications (1)

Publication Number Publication Date
AU2003287833A1 true AU2003287833A1 (en) 2004-07-14

Family

ID=32682047

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287833A Abandoned AU2003287833A1 (en) 2002-12-19 2003-12-19 Use of aglycon protopanaxatriol in cancer therapy

Country Status (2)

Country Link
AU (1) AU2003287833A1 (en)
WO (1) WO2004056371A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58131999A (en) * 1982-01-30 1983-08-06 Osaka Chem Lab Antitumor agent
JP3160313B2 (en) * 1991-07-01 2001-04-25 勲 北川 Anticancer drug
JPH08291194A (en) * 1995-04-18 1996-11-05 Happy World:Kk Ginseng sapogenin and its production
KR0164266B1 (en) * 1996-02-22 1999-01-15 오오니시 쿠니히로 Metabolites of ginseng saponins by human intestinal bacteria and its preparation for an anticancer
CN1431910A (en) * 2000-05-01 2003-07-23 不列颠哥伦比亚大学 Ginsenoside chemotherapy
US6888014B2 (en) * 2001-07-24 2005-05-03 Panagin Pharmaceuticals Inc. Dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
US20030092638A1 (en) * 2001-09-21 2003-05-15 Dong Huang Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
BR0311866A (en) * 2002-06-11 2005-03-15 Panagin Pharmaceuticals Inc Saponin or sapogenin compositions for cancer therapy

Also Published As

Publication number Publication date
WO2004056371A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002352799A1 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003219555A1 (en) Depsipeptide for therapy of kidney cancer
EP1594433B8 (en) Cancer therapy sensitizer
EP1594433A3 (en) Cancer therapy sensitizer
AU2003233733A1 (en) Compositions for cancer therapy saponins or sapogenins
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2003230849A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003287834A1 (en) Use of aglycon protopanaxadiol in cancer therapy
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2003291896A1 (en) Saponins and sapogenins for use in combination therapy for cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003287833A1 (en) Use of aglycon protopanaxatriol in cancer therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase